Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma

Eduard Teixidor; Elia Sais; Carmen Amalia Vásquez; Walter Carbajal; Alejandro Hernández; Gloria Sánchez; Angel Izquierdo; Sara Verdura; Javier A. Menéndez; Joaquim Bosch-Barrera

doi:10.18632/oncotarget.28471

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Addendum:

Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma

PDF | How to cite

Oncotarget. 2023; 14:668-668. https://doi.org/10.18632/oncotarget.28471

Metrics: PDF 673 views | ?

Eduard Teixidor¹, Elia Sais¹, Carmen Amalia Vásquez², Walter Carbajal¹, Alejandro Hernández¹, Gloria Sánchez³, Angel Izquierdo¹, Sara Verdura^4,5, Javier A. Menéndez^4,5 and Joaquim Bosch-Barrera^1,5,6

¹Department of Medical Oncology, Catalan Institute of Oncology, Doctor Josep Trueta University Hospital, Girona, Spain
²Department of Anatomical Pathology, Dr. Josep Trueta Hospital of Girona, Girona, Catalonia, Spain
³Department of Radiology, Diagnostic Imaging Institute, Doctor Josep Trueta University Hospital, Girona, Spain
⁴ProCURE (Program Against Cancer Therapeutic Resistance), Metabolism and Cancer Group, Catalan Institute of Oncology, Girona, Catalonia, Spain
⁵Girona Biomedical Research Institute (IDIBGi), Girona, Catalonia, Spain
⁶Department of Medical Sciences, Medical School, University of Girona, Girona, Spain

Published: July 01, 2023

Copyright: © 2023 Teixidor et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: Patient consent was required and obtained.

Original article: Oncotarget. 2018; 9:33043-33049. DOI: https://doi.org/10.18632/oncotarget.25984.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28471

Publication Alerts

Post-Publication Promotion

Publication Discount

Addendum:

Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma